CN110151922B - Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN110151922B CN110151922B CN201910577444.4A CN201910577444A CN110151922B CN 110151922 B CN110151922 B CN 110151922B CN 201910577444 A CN201910577444 A CN 201910577444A CN 110151922 B CN110151922 B CN 110151922B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicinal
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 131
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 64
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 58
- 229940079593 drug Drugs 0.000 claims abstract description 37
- 241000282817 Bovidae Species 0.000 claims abstract description 22
- 241000218176 Corydalis Species 0.000 claims abstract description 22
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 21
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 21
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 21
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 21
- 241000157352 Uncaria Species 0.000 claims abstract description 21
- 241000305491 Gastrodia elata Species 0.000 claims abstract description 20
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 20
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 18
- 241000241550 Cyathula Species 0.000 claims abstract description 18
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 17
- 240000006023 Trichosanthes kirilowii Species 0.000 claims abstract description 17
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 claims abstract description 17
- 240000001638 Scurrula parasitica Species 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 230000002829 reductive effect Effects 0.000 claims description 39
- 238000002156 mixing Methods 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 241000723353 Chrysanthemum Species 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 241000488974 Loranthus Species 0.000 claims description 12
- 230000003071 parasitic effect Effects 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 238000007796 conventional method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 49
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 39
- 208000026435 phlegm Diseases 0.000 abstract description 39
- 210000004369 blood Anatomy 0.000 abstract description 37
- 239000008280 blood Substances 0.000 abstract description 37
- 210000004185 liver Anatomy 0.000 abstract description 23
- 230000001914 calming effect Effects 0.000 abstract description 7
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 241000721047 Danaus plexippus Species 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 244000052769 pathogen Species 0.000 abstract description 4
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract description 3
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 241000212322 Levisticum officinale Species 0.000 abstract description 2
- 239000001645 levisticum officinale Substances 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 2
- 230000036772 blood pressure Effects 0.000 description 43
- 230000036407 pain Effects 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 22
- 208000002193 Pain Diseases 0.000 description 21
- 208000012886 Vertigo Diseases 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 231100000889 vertigo Toxicity 0.000 description 21
- 206010008479 Chest Pain Diseases 0.000 description 20
- 208000002173 dizziness Diseases 0.000 description 20
- 230000001603 reducing effect Effects 0.000 description 20
- 230000017531 blood circulation Effects 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 11
- 230000035487 diastolic blood pressure Effects 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 208000031225 myocardial ischemia Diseases 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000000006 Nitroglycerin Substances 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 229960003711 glyceryl trinitrate Drugs 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000243684 Lumbricus Species 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000157373 Uncaria rhynchophylla Species 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of loranthus parasiticus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae. The traditional Chinese medicine composition provided by the invention has reasonable monarch, minister, assistant and guide compatibility, and the four medicines of pseudo-ginseng, salvia miltiorrhiza, gastrodia elata and uncaria are monarch medicines; the antelope horn, the earthworm, the szechuan lovage rhizome and the corydalis tuber are ministerial drugs, the loranthus parasiticus, the snakegourd fruit, the pericarpium citri reticulatae, the rhizoma alismatis and the chrysanthemum are adjuvant drugs, and the medicinal cyathula root is a conductant drug, so that the traditional Chinese medicine has the effects of activating blood and calming the liver, eliminating turbid pathogen and dredging collaterals, and eliminating dampness and phlegm, and is suitable for treating patients with phlegm stagnation and obstruction as well as liver depression and dampness obstruction type angina and hypertension.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and a preparation method thereof.
Background
Because the development speed of the modern society is fast, the rhythm of work, study and life is accelerated, the competition in all aspects is stronger, and the incidence rate of angina pectoris combined with hypertension is increased. Coronary atherosclerotic heart disease refers to heart disease caused by stenosis or obstruction of blood vessel cavity due to coronary atherosclerosis, or myocardial ischemia and anoxia or necrosis due to coronary artery functional change spasm, and is called coronary heart disease for short. Angina pectoris is a kind of coronary heart disease, and is a clinical syndrome with paroxysmal chest pain as main symptom caused by myocardial ischemia and anoxia. Hypertension is characterized by the rise of systemic arterial pressure, is the first risk factor of cardiovascular and cerebrovascular diseases, and the hemodynamic changes caused by continuously rising blood pressure can activate blood platelets in blood, promote coronary atherosclerotic lesions, and cause angina pectoris caused by myocardial ischemia and anoxia. The knowing rate, the control rate and the treatment rate of the hypertension are low in China, the disability rate and the fatality rate are high, and the prevention and control situation is severe. The change of the heart structure and function caused by the increase of the systemic arterial pressure of a patient and the poor control of hypertension for a long time is called as hypertensive heart disease, and the heart failure finally occurs after the myocardial contractile function declines gradually. There are studies showing that 70% of heart failure is caused by hypertension, with angina pectoris complicated by hypertension being the chief culprit.
According to traditional Chinese medicine, angina pectoris is combined with chest stuffiness and vertigo caused by hypertension. Angina pectoris is the chest stuffiness and pain. The disease name is the earliest one in Huangdi's inner classic, which says "lung is big and more fluid, good at chest bi-syndrome". It is a disease with abundant phlegm-dampness and easy to cause obstruction of qi in the chest. Hypertension belongs to the category of vertigo. Vertigo is recorded in the interior (classic) as in the plain questions and the essential essentials: wind-cold syndrome all belongs to the liver. It is pointed out that vertigo is closely related to the liver. Zhang Zhongjing, Shang Han Lun, describes vertigo as "dizzy", "dizzy" and so on, but he proposes the theory of "dizzy due to phlegm". Yu and Yu (Yi Zong Zheng Xue, vertigo) indicates that it is indicated that the syndrome of dizziness caused by fat white in the human body should be treated with the action of clearing phlegm and purging fire first and tonifying qi; for people who are black, thin and dizzy, they are indicated for nourishing yin to reduce fire and with liver-suppressing agent. Points out the key of eliminating dampness and eliminating phlegm in the treatment of vertigo.
The human body is happy to eat the food, is fat, sweet and thick, can damage the spleen and the stomach, enables the spleen to lose health and transportation, transport and transform water-dampness dysfunction, gathers dampness to form phlegm, phlegm retention pathogen can not be found everywhere, goes up to the heart and the chest, obstructs heart vessels to cause chest stuffiness and pains, and remains in the head to cause dizziness; stagnation of qi activity, retention of turbid phlegm, stagnation of phlegm and blood stasis, obstruction of heart vessels to cause chest distress and palpitation, obstruction of clear orifices and blood to cause vertigo; the chest stuffiness, the unsmooth pulse channel and the head blood supply obstacle are caused by qi impairment due to food fullness, weakness of qi circulation and unsmooth qi and blood circulation, so that vertigo is caused; in cold weather, phlegm-dampness and blood stasis are combined, blood congeals when meeting cold, and obstruction of blood vessels causes chest distress and vertigo. The simultaneous treatment of different diseases is the characteristic of the traditional Chinese medicine for treating diseases, and in the aspect of pathogenesis, phlegm, dampness and stasis are used as pathological products and pathogenic factors, and the three are causal to each other and are the main causes of angina pectoris and hypertension. Therefore, the key to treat diseases is eliminating phlegm dampness, promoting blood circulation by removing blood stasis, calming the liver and reducing blood pressure.
Although the existing western medicines have more medicines for treating angina and hypertension, if the medicines are taken for a long time, the patients are easy to have side effects of dizziness, headache, accelerated heartbeat, flushing, nephrotoxicity and the like, and the medicine resistance is easy to generate, so that the curative effect is poor. Therefore, the research of the field is focused on finding the medicine with good treatment effect and small toxic and side effect, and the traditional Chinese medicine has unique advantages in treating the diseases, so that the research of the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension is necessary.
Disclosure of Invention
The invention aims to solve the technical defects and provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and a preparation method thereof. The traditional Chinese medicine composition adopts holistic concept and dialectical treatment according to the traditional Chinese medicine characteristic therapy of activating blood circulation and dredging channels, dialectical treatment and dialectical treatment are combined, and the medicine is flexibly prepared according to the specific conditions of wind, fire, phlegm, stasis and deficiency, so that all medicines in the composition are in synergistic effect, the medicines are reasonably compatible, the used medicines are simple and easy to find, the toxic and side effects are small, and the traditional Chinese medicine composition has a remarkable treatment effect on the aspect of treating angina and hypertension.
In order to achieve the purpose, the invention adopts the technical scheme that:
the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension is prepared from the following raw material medicines in parts by weight:
10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of loranthus parasiticus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae.
Preferably, the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension is prepared from the following raw material medicines in parts by weight:
10-25 parts of pseudo-ginseng, 6-25 parts of salvia miltiorrhiza, 5-20 parts of earthworm, 6-30 parts of ligusticum wallichii, 8-30 parts of corydalis tuber, 12-30 parts of gastrodia elata, 8-30 parts of uncaria, 6-15 parts of antelope horn, 10-20 parts of loranthus parasiticus, 5-15 parts of chrysanthemum, 5-20 parts of rhizoma alismatis, 8-35 parts of medicinal cyathula root, 6-30 parts of trichosanthes kirilowii maxim and 6-15 parts of pericarpium citri reticulatae.
In order to improve the quality and the effect of the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension in the production process and prolong the effective period of the medicine, the preparation method of the traditional Chinese medicine composition is provided:
s1: weighing 10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of parasitic loranthus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae according to parts by weight for later use;
s2: mixing the raw materials weighed by S1, adding ethanol 4-8 times of the total weight of the raw materials, soaking for 1-1.5 h, extracting at 30-35 deg.C for 1-1.5 h for 2-4 times, filtering to obtain residue, and mixing extractive solutions; filtering the extracting solution by using a 100-150-mesh filter screen, then carrying out ultrafiltration by using an ultrafiltration column with the cut-off molecular weight of 5000-12000, carrying out reduced pressure concentration on the ultrafiltrate to obtain an extract with the relative density of 1.2-1.25 at 65-75 ℃, and standing to obtain a component alpha;
s3: adding 8-12 times of distilled water into the residue extracted by the ethanol of S2, heating and refluxing for extraction for 2-4 times, each time for 1.0-2.5 h, mixing the extractive solutions, and standing to obtain a component beta;
s4: mixing alpha and beta, filtering, concentrating under reduced pressure to obtain medicinal liquid with concentration of 1.0-1.2 g/mL, refining and purifying to obtain Chinese medicinal extract, and making the extract into pharmaceutically acceptable medicinal preparation by conventional method of Chinese patent medicine.
Preferably, the pharmaceutical preparation is in the form of tablets, capsules, granules, dispersible tablets or pills.
Preferably, in S4, the specific process of refining and purifying is as follows:
adsorbing the concentrated medicinal liquid with macroporous adsorbent resin column, eluting with 10-12 times of distilled water, eluting with 4-6 times of ethanol, collecting ethanol eluate, and removing solvent to obtain Chinese medicinal extract.
The invention also provides another preparation method of the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which comprises the following steps:
step 1: weighing 10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of parasitic loranthus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae according to parts by weight for later use;
step 2: crushing the raw materials weighed in the step 1 into particles, soaking the particles in water for 1-2 hours to enable the medicines to be thoroughly wetted, then adding water with the weight being 8-12 times that of the raw materials into the raw materials for decocting, boiling the raw materials with strong fire, changing the raw materials into slow fire after the water is boiled, decocting for 1.5-2 hours, filtering to obtain liquid medicine, and separating medicine residues;
adding water with the amount of 3-6 times of the medicinal materials into the residue, decocting for 1-2 hr, filtering to obtain medicinal liquid, separating out residue, and repeatedly extracting the residue for 2-3 times;
filtering the decoctions, and mixing to obtain filtrate;
and step 3: concentrating the filtrate obtained in step 2 under reduced pressure to obtain concentrated solution with relative density of 1.1-1.2 at 70-80 deg.C, and standing at 0-5 deg.C for 18-24 hr to obtain refrigerated solution;
and 4, step 4: mixing the refrigerating fluid obtained in the step 3 with diatomite according to the weight ratio of 1:2, filtering, concentrating the filtrate under reduced pressure, drying into powder, and preparing the powder into a pharmaceutically acceptable medicinal preparation according to a conventional method.
Preferably, the pharmaceutical preparation is in the form of tablets, capsules, granules, dispersible tablets or pills.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention selects each raw material medicine and strictly controls the proportion thereof under the summary of the traditional Chinese medicine theory and clinical practice experience, has precise and appropriate formula, follows the principles of syndrome differentiation and treatment of the traditional Chinese medicine and the four-qi and five-flavor of the traditional Chinese medicine, and focuses on the pathogenesis of angina pectoris combined with hypertension; the traditional Chinese medicine composition adopts a comprehensive conditioning method of traditional Chinese medicine, and has the effects of removing blood stasis, relieving pain, promoting qi circulation, activating blood circulation, dredging blood vessels of the whole body and promoting blood circulation, calming the liver and reducing blood pressure; on the other hand, the medicine has the effects of eliminating dampness and phlegm, and eliminating dampness and phlegm by qi accumulation, and is particularly suitable for treating the patients with angina pectoris complicated with hypertension due to phlegm stagnation and obstruction of qi stagnation and liver depression and dampness obstruction. In clinical tests, the traditional Chinese medicine composition has an obvious treatment effect, the significant efficiency reaches 82%, and the total effective rate reaches 98%;
2. the traditional Chinese medicine composition provided by the invention has reasonable monarch, minister, assistant and guide compatibility of each raw material medicine, and the four medicines of pseudo-ginseng, salvia miltiorrhiza, gastrodia elata and uncaria are monarch medicines; cornu Saigae Tataricae, Lumbricus, rhizoma Ligustici Chuanxiong and rhizoma corydalis as ministerial drugs, herba Taxilli, fructus Trichosanthis, pericarpium Citri Tangerinae, Alismatis rhizoma and flos Chrysanthemi as adjuvant drugs, and radix Cyathulae as messenger drug; the raw materials are compatible for use, and have the effects of promoting blood circulation, calming the liver, reducing blood pressure, eliminating turbid pathogen, dredging collaterals, relieving pain, increasing coronary blood flow, reducing blood pressure, resisting coagulation and reducing blood fat. The medicine has strict medicine proportion, is assistant and guide, treats both principal and secondary aspects of diseases, promotes blood circulation, reduces phlegm, soothes liver, eliminates dampness, and is suitable for patients with angina pectoris complicated with hypertension caused by phlegm stagnation and arthralgia and liver depression and dampness obstruction.
Wherein Notoginseng radix, Saviae Miltiorrhizae radix, rhizoma Gastrodiae and ramulus Uncariae cum uncis are used as principal drugs; pseudo-ginseng can remove blood stasis and promote tissue regeneration, is a good product for treating symptoms of blood stasis, has the effects of resisting platelet aggregation and thrombolysis, can reduce blood pressure and slow down heart rate, and has a protective effect on arrhythmia induced by various medicines; can reduce myocardial oxygen consumption, dilate cerebral vessels, and enhance cerebral vessel flow; the salvia miltiorrhiza is commonly used for blood stasis and cardiodynia, vexation and insomnia, can expand coronary artery, increase coronary blood flow, improve myocardial ischemia, promote recovery of myocardial ischemia or injury, reduce myocardial infarction range, protect ischemic myocardium, reduce blood viscosity, inhibit platelet aggregation, regulate blood fat, inhibit formation of atherosclerotic plaque, expand blood vessel and reduce blood pressure; the pseudo-ginseng and the salvia miltiorrhiza have excellent effects of promoting blood circulation and removing blood stasis, enhance the protective effect on myocardial infarction tissues, increase coronary flow, reduce fat and stabilize plaques, and can reduce blood pressure without influencing myocardial blood supply; rhizoma Gastrodiae has effects of reducing resistance of peripheral blood vessel, cerebral vessels and coronary blood vessels, lowering blood pressure, relieving pain and resisting inflammation; the uncaria and uncaria rhynchophylla total alkali has the effects of reducing blood pressure, inhibiting platelet aggregation, resisting thrombus, reducing blood fat and the like on the normal blood pressure and the high blood pressure of various animals; the gastrodia elata is matched with the uncaria to calm the liver and calm the wind, so that the blood pressure is reduced; the four medicines are monarch medicines, and have the effects of promoting blood circulation, removing blood stasis, eliminating turbid pathogen, dredging collaterals, calming liver wind, increasing myocardial blood supply, reducing blood fat, stabilizing plaque, lowering blood pressure and protecting damaged myocardium.
Antelope horn, earthworm, Szechuan lovage rhizome and corydalis tuber are used as ministerial drugs. The antelope horn has the functions of calming liver, stopping endogenous wind, clearing liver and improving eyesight, and the decoction or alcohol extract of the antelope horn has the function of reducing blood pressure, and the small dosage of the antelope horn can strengthen the heart contraction of the in vitro toad; the tincture and decoction of the earthworm have slow and lasting blood pressure reducing effect; the Lumbricus extract has fibrinolysis and anticoagulant effects; rhizoma Ligustici Chuanxiong ascends to the head and eyes, and has effects of regulating menstruation, promoting stasis, increasing coronary artery, increasing coronary blood flow, improving myocardial blood oxygen supply, and reducing myocardial oxygen consumption, and the decoction has tranquilizing effect on animal central nervous system and has obvious and lasting blood pressure lowering effect; corydalis tuber can promote the circulation of qi in blood and stagnation of qi in blood, so that it is specially used for curing pain of upper and lower parts of the whole body, and its corydalis tuber alcohol extract can expand coronary artery, reduce coronary artery resistance and increase coronary blood flow; the total alkali can resist arrhythmia and myocardial ischemia, dilate peripheral blood vessels and reduce blood pressure; the four medicines are ministerial, calm liver and reduce blood pressure, relieve pain and activate blood, increase the effect of promoting blood circulation and relieving pain to coronary heart disease, and have obvious and lasting effect of reducing blood pressure.
Herba Taxilli, fructus Trichosanthis, pericarpium Citri Reticulatae Chachiensis, rhizoma Alismatis, and flos Chrysanthemi as adjuvant drugs. Herba Taxilli has effects of dispelling pathogenic wind and removing dampness, nourishing liver and kidney, strengthening tendons and bones, and lowering blood pressure; the injection has effects of dilating coronary blood vessel and slowing down heart rate; the saponin and the total amino acid in the peel contained in the snakegourd fruit have the function of eliminating phlegm; the snakegourd fruit injection has the function of dilating the coronary artery of the isolated heart of the guinea pig; has obvious protective effect on acute myocardial ischemia caused by posterior pituitary; and has blood lipid reducing effect; the pericarpium citri reticulatae is used for regulating qi, stimulating appetite, drying dampness and reducing phlegm, can excite the heart, enhance myocardial contraction force and increase coronary blood flow, and has a certain prevention effect on arteriosclerosis caused by high-fat diet; alismatis rhizoma has diuretic, blood pressure lowering, blood sugar lowering, and fatty liver resisting effects; the flos Chrysanthemi preparation has effects of dilating coronary artery, increasing coronary blood flow, increasing myocardial oxygen consumption, lowering blood pressure, shortening blood coagulation time, relieving fever, resisting inflammation, and tranquilizing mind. The five medicines are adjuvant medicines and have the effects of enhancing the drug effect, promoting blood circulation, calming the liver, reducing blood pressure, promoting qi circulation, removing blood stasis, relieving pain, reducing phlegm, promoting diuresis, dredging collaterals, enhancing the effect of reducing blood pressure, reducing fat and stabilizing plaques.
Radix cyathulae is used as a messenger drug, and the radix cyathulae decoction has the effects of transient blood pressure reduction and mild diuresis, can reduce the viscosity of whole blood, has the effects of anticoagulation and blood fat reduction, can obviously reduce blood sugar, is mainly used for promoting qi circulation, soothing liver, reducing phlegm, eliminating dampness and dissolving turbidity, and has the effects of blood pressure reduction, diuresis, anticoagulation and blood fat reduction.
Detailed Description
In order that those skilled in the art will better understand the technical solutions of the present invention to practice, the present invention will be further described with reference to the following specific examples, but the present invention should not be construed as being limited thereto. The experimental procedures, in which specific conditions are not indicated in the examples below, were carried out according to the conventional methods and conditions in the art.
The technical solution of the present invention will be further described with reference to some specific embodiments.
Example 1
The embodiment provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which is prepared from the following raw materials in parts by weight: 15 parts of pseudo-ginseng, 30 parts of salvia miltiorrhiza, 20 parts of earthworm, 28 parts of ligusticum wallichii, 18 parts of corydalis tuber, 28 parts of gastrodia elata, 18 parts of uncaria, 6 parts of antelope horn, 15 parts of parasitic loranthus, 15 parts of chrysanthemum, 10 parts of rhizoma alismatis, 16 parts of medicinal cyathula root, 25 parts of trichosanthes kirilowii maxim and 8 parts of pericarpium citri reticulatae.
The present application also provides a preparation method of the above traditional Chinese medicine composition, comprising the following steps: weighing the raw materials according to the weight, mixing the raw materials, adding ethanol which is 5 times of the total weight of the raw materials, soaking for 1.0h, heating and extracting for 3 times, each time for 1h, and combining the extracting solutions; standing, collecting supernatant, filtering with 140 mesh, ultrafiltering with ultrafiltration column with cut-off molecular weight of 5000, concentrating ultrafiltrate under reduced pressure to obtain extract with relative density of 1.15 at 70 deg.C, and standing to obtain component alpha; adding 8 times of distilled water into the residues after ethanol extraction, heating and refluxing for extraction for 2 times, each time for 1.0h, mixing the extractive solutions, and standing to obtain component beta; mixing the alpha component and the beta component, carrying out suction filtration, then carrying out reduced pressure concentration until the concentration of the liquid medicine is 1.0g/mL, then carrying out adsorption through a macroporous adsorption resin column, eluting with distilled water with the volume 8 times that of the resin column, eluting with absolute ethyl alcohol with the volume 5 times that of the resin column, collecting an ethanol eluent, removing a solvent to obtain medicinal powder, and filling the medicinal powder into capsules, wherein each capsule is 1.2 g.
Example 2
The embodiment provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which is prepared from the following raw materials in parts by weight: 25 parts of pseudo-ginseng, 20 parts of salvia miltiorrhiza, 15 parts of earthworm, 12 parts of ligusticum wallichii, 25 parts of corydalis tuber, 26 parts of gastrodia elata, 30 parts of uncaria, 10 parts of antelope horn, 20 parts of parasitic loranthus, 20 parts of chrysanthemum, 15 parts of rhizoma alismatis, 24 parts of medicinal cyathula root, 28 parts of trichosanthes kirilowii maxim and 10 parts of pericarpium citri reticulatae.
The embodiment also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: weighing the raw materials according to the weight, mixing the raw materials, adding ethanol which is 6 times of the total weight of the raw materials, soaking for 2.0h, heating and extracting for 2 times, 2h each time, and combining the extracting solutions; standing, collecting supernatant, filtering with 120 mesh, ultrafiltering with an ultrafiltration column with cut-off molecular weight of 8000, concentrating ultrafiltrate under reduced pressure to obtain extract with relative density of 1.18 at 60 deg.C, and standing to obtain component alpha; adding 10 times of distilled water into the residues after ethanol extraction, heating and refluxing for extraction for 3 times, each time for 2.0h, mixing the extractive solutions, and standing to obtain component beta; mixing the alpha component and the beta component, carrying out suction filtration, then carrying out reduced pressure concentration until the concentration of the liquid medicine is 1.02g/mL, then carrying out adsorption through a macroporous adsorption resin column, eluting with 10 times of distilled water, eluting with 6 times of absolute ethyl alcohol, collecting the ethanol eluent, removing the solvent to obtain medicinal powder, and filling the medicinal powder into capsules, wherein each capsule is 0.8 g.
Example 3
The embodiment provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which is prepared from the following raw materials in parts by weight: 20 parts of pseudo-ginseng, 18 parts of salvia miltiorrhiza, 12 parts of earthworm, 18 parts of ligusticum wallichii, 20 parts of corydalis tuber, 30 parts of gastrodia elata, 25 parts of uncaria, 12 parts of antelope horn, 16 parts of parasitic loranthus, 12 parts of chrysanthemum, 18 parts of rhizoma alismatis, 28 parts of medicinal cyathula root, 26 parts of trichosanthes kirilowii maxim and 9 parts of pericarpium citri reticulatae.
The embodiment also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: weighing the raw materials according to the weight, mixing the raw materials, adding ethanol which is 6 times of the total weight of the raw materials, soaking for 2.0h, heating and extracting for 3 times, 2h each time, and mixing the extracting solutions; standing, collecting supernatant, filtering with 140 mesh, ultrafiltering with ultrafiltration column with cut-off molecular weight of 10000, concentrating ultrafiltrate under reduced pressure to obtain extract with relative density of 1.18 at 70 deg.C, and standing to obtain component alpha; adding 12 times of distilled water into the residues after ethanol extraction, heating and refluxing for extraction for 3 times, each time for 2.0h, mixing the extractive solutions, and standing to obtain component beta; mixing the alpha component and the beta component, carrying out suction filtration, then carrying out reduced pressure concentration until the concentration of the liquid medicine is 1.05g/mL, then carrying out adsorption through a macroporous adsorption resin column, eluting with distilled water with the volume 12 times that of the resin column, eluting with absolute ethyl alcohol with the volume 6 times that of the resin column, collecting an ethanol eluent, removing a solvent to obtain medicinal powder, and filling the medicinal powder into capsules, wherein each capsule is 1.5 g.
Example 4
The embodiment provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which is prepared from the following raw materials in parts by weight: 22 parts of pseudo-ginseng, 24 parts of salvia miltiorrhiza, 20 parts of earthworm, 24 parts of ligusticum wallichii, 22 parts of corydalis tuber, 32 parts of gastrodia elata, 16 parts of uncaria, 14 parts of antelope horn, 24 parts of parasitic loranthus, 16 parts of chrysanthemum, 14 parts of rhizoma alismatis, 32 parts of medicinal cyathula root, 24 parts of trichosanthes kirilowii maxim and 12 parts of pericarpium citri reticulatae.
The embodiment also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: weighing the raw materials according to the weight, mixing the raw materials, adding ethanol which is 5 times of the total weight of the raw materials, soaking for 2.0h, heating and extracting for 3 times, 2h each time, and mixing the extracting solutions; standing, collecting supernatant, filtering with 140 mesh, ultrafiltering with ultrafiltration column with cut-off molecular weight of 10000, concentrating ultrafiltrate under reduced pressure to obtain extract with relative density of 1.2 at 70 deg.C, and standing to obtain component alpha; adding 10 times of distilled water into the residues after ethanol extraction, heating and refluxing for extraction for 3 times, each time for 2.0h, mixing the extractive solutions, and standing to obtain component beta; mixing the alpha component and the beta component, carrying out suction filtration, then carrying out reduced pressure concentration until the concentration of the liquid medicine is 1.1g/mL, then carrying out adsorption through a macroporous adsorption resin column, eluting with distilled water with the volume 12 times that of the resin column, eluting with absolute ethyl alcohol with the volume 6 times that of the resin column, collecting an ethanol eluent, removing a solvent to obtain medicinal powder, and filling the medicinal powder into capsules, wherein each capsule is 1.0 g.
Example 5
The embodiment provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which comprises the following raw materials in parts by weight: 28 parts of pseudo-ginseng, 28 parts of salvia miltiorrhiza, 22 parts of earthworm, 36 parts of ligusticum wallichii, 30 parts of corydalis tuber, 36 parts of gastrodia elata, 36 parts of uncaria, 16 parts of antelope horn, 22 parts of parasitic loranthus, 18 parts of chrysanthemum, 8 parts of rhizoma alismatis, 35 parts of medicinal cyathula root, 30 parts of trichosanthes kirilowii maxim and 15 parts of pericarpium citri reticulatae.
The embodiment also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: weighing the raw materials according to the weight, removing impurities from the raw materials, drying in the air, crushing into granules, soaking in water for 1h, decocting the soaked raw materials in water for 2 times, adding water 8 times the total amount of the raw materials for the first time, decocting for 1.5h, taking the decoction, and filtering; then adding 3 times of water of the total raw materials, decocting for 1h, mixing the decoctions obtained in 2 times, and filtering to obtain filtrate; concentrating the filtrate under reduced pressure to obtain concentrated solution with relative density of 1.2 at 80 deg.C, and refrigerating at 0-5 deg.C for 24 hr; mixing the obtained cold storage solution with diatomaceous earth at a mass ratio of 1:2, filtering, concentrating the filtrate under reduced pressure, drying into powder, and making into capsule with a weight of 0.8g per capsule.
Example 6
The embodiment provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which comprises the following raw materials in parts by weight: 10 parts of pseudo-ginseng, 20 parts of salvia miltiorrhiza, 5 parts of earthworm, 16 parts of ligusticum wallichii, 26 parts of corydalis tuber, 21 parts of gastrodia elata, 18 parts of uncaria, 10 parts of antelope horn, 12 parts of parasitic loranthus, 8 parts of chrysanthemum, 18 parts of rhizoma alismatis, 30 parts of medicinal cyathula root, 15 parts of trichosanthes kirilowii maxim and 10 parts of pericarpium citri reticulatae.
The embodiment also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: weighing the raw materials according to the weight, removing impurities from the raw materials, drying in the air, crushing into granules, soaking in water for 2h, decocting the soaked raw materials in water for 3 times, adding water 10 times of the total amount of the raw materials for the first time, decocting for 2h, taking the decoction, and filtering; then adding water in an amount which is 5 times of the total amount of the raw materials, decocting for 1.2h, mixing the decoctions obtained in 2 times, and filtering to obtain filtrate; concentrating the filtrate under reduced pressure to obtain concentrated solution with relative density of 1.1 at 70 deg.C, and refrigerating at 0-5 deg.C for 20 hr; mixing the obtained cold storage solution with diatomaceous earth at a mass ratio of 1:2, filtering, concentrating the filtrate under reduced pressure, drying into powder, and making into capsule, 2g per capsule.
Example 7
The embodiment provides a traditional Chinese medicine composition for treating angina pectoris complicated with hypertension, which comprises the following raw materials in parts by weight: 30 parts of pseudo-ginseng, 6 parts of salvia miltiorrhiza, 25 parts of earthworm, 6 parts of ligusticum wallichii, 32 parts of corydalis tuber, 12 parts of gastrodia elata, 8 parts of uncaria, 18 parts of antelope horn, 10 parts of parasitic loranthus, 20 parts of chrysanthemum, 25 parts of rhizoma alismatis, 36 parts of medicinal cyathula root, 6 parts of trichosanthes kirilowii maxim and 18 parts of pericarpium citri reticulatae.
The embodiment also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: weighing the raw materials according to the weight, removing impurities from the raw materials, drying in the air, crushing into granules, soaking in water for 2h, decocting the soaked raw materials in water for 3 times, adding water in an amount which is 12 times of the total amount of the raw materials for the first time, decocting for 2h, taking the decoction, and filtering; then adding 6 times of water of the total raw materials, decocting for 1.2h, mixing the decoctions obtained in 2 times, and filtering to obtain filtrate; concentrating the filtrate under reduced pressure to obtain concentrated solution with relative density of 1.2 at 80 deg.C, and refrigerating at 0-5 deg.C for 24 hr; mixing the obtained cold storage solution with diatomaceous earth at a mass ratio of 1:2, filtering, concentrating the filtrate under reduced pressure, drying into powder, and making into capsule with a weight of 1.2g per capsule.
Examples 1 to 7 all provide the Chinese medicinal composition for treating angina pectoris complicated with hypertension, and since the treatment effects of the Chinese medicinal compositions provided in examples 1 to 7 are substantially parallel, the effects of the present invention will be described below by taking only the Chinese medicinal composition prepared in example 3 as an example.
First, curative effect experiment
1. Rat model establishment
80 SPF SD rats with half male and female bodies and weight of 180-220 g are taken. 60 of the rats (hermaphrodite halves) were anesthetized with 10% chloral hydrate (0.4mL/100g) by intraperitoneal injection, then fixed on the operating table supine, the abdominal body hair was cut off, sterilized with 5% iodophor, deiodinated with 75% alcohol, and draped. Opening the abdominal cavity along the operation incision of the abdominal midline, carefully and obtusely separating the left renal artery according to aseptic operation, penetrating 3-0 aseptic silk thread, closely and parallelly placing an acupuncture needle with the diameter of 0.25mm and the long axis of the renal artery blood vessel, tightly tying the renal artery and the acupuncture needle by the 3-0 aseptic silk thread, then drawing out the acupuncture needle, and causing a unilateral renal artery stenosis model, wherein the right artery is not tied. The remaining 20 rats (hermaphroditic halves) were operated and threaded only without ligation of the left renal artery, and served as sham controls.
All rats were post-operatively injected with penicillin (40 ten thousand U/d) intraperitoneally for 3 consecutive days to prevent infection. Each group of animals was fed food and water in a standard feeding environment (temperature and humidity ranges 22-26 ℃ and 53-60%, respectively).
After 10 weeks of molding, 60 successfully molded rats are selected, and the sodium pentobarbital is 30 mg/kg-1The blood pressure of each model rat is measured by a tail sleeve method of a BP-100A full-automatic rat noninvasive blood pressure measuring system after intraperitoneal injection anesthesia, and the blood pressure is used as the blood pressure value of a hypertension model rat before administration. Dividing randomly into 3 groups according to blood pressure value, including model group, captopril group, and Chinese medicinal administration group, wherein each group contains 20 drugs, and each half of male and female. The sham-operated control rats were anesthetized using the same method, and their blood pressures were measured by the tail-cap method as blood pressure values of the sham-operated control rats before administration.
2. Experimental methods
Each group of rats was administered in groups:
sham-operated controls: the stomach was perfused with physiological saline at 1mL/100g body weight;
model group: the stomach was perfused with physiological saline at 1mL/100g body weight;
captopril group: preparing mixed solution by adding 0.2g of captopril and 100mL of physiological saline, and performing intragastric administration according to the weight of 1mL/100 g;
a traditional Chinese medicine administration group: 10g of the powder of example 3 was mixed with 1000mL of physiological saline to prepare a mixture, and the mixture was administered to the stomach at a concentration of 1mL/100g of body weight.
Each group was gavaged 1 time per day for 4 consecutive weeks.
3. Results of the experiment
The results are shown in table 1, and it can be seen from table 1 that the systolic pressure and diastolic pressure of the rats in the group administered with the traditional Chinese medicine are both significantly lower than those in the model group (P <0.05), and the antihypertensive effect is close to that of the captopril group.
TABLE 1 systolic and diastolic blood pressure in rats
| Group of | Systolic pressure (mmHg) | Diastolic blood pressure (mmHg) |
| Sham control group | 110.25±5.25* | 76.15±3.32* |
| Model set | 159.11±8.17 | 119.64±4.57 |
| Captopril group | 120.19±6.38* | 85.46±3.73* |
| Traditional Chinese medicine administration group | 123.52±5.68* | 86.13±3.69* |
Note: p <0.05 compared to model group.
Second, clinical trial
I, clinical data
1.1 general data
200 outpatient angina pectoris patients with hypertension were treated since 2010. Wherein 100 cases of male and 100 cases of female are 30-70 years old, and the average age is 61 years old; the disease course is 1.5-10 years, 82 cases with the disease course less than 2 years, 67 cases with the disease course less than 2-6 years, and 51 cases with the disease course less than 6-10 years.
1.2 diagnostic criteria
Refer to the standard of treating thoracic obstruction (angina pectoris) and vertigo (hypertension) in "clinical practice and treatment guide & cardiovascular branch book".
1.2.1 Chinese medicine diagnostic Standard
Chest distress can cause suffocation and pain, or pain induced to shoulder and back, shortness of breath, dyspnea, obesity, excessive phlegm, vertigo, headache, head wrapping, chest distress, vomiting phlegm and saliva. A greasy or slippery coating on the tongue and a slippery pulse.
1.2.2 Western diagnostic standards
Angina pectoris diagnosis standard:
stable angina pectoris: is characterized by transient chest pain attacks induced by exercise or other conditions that increase myocardial oxygen demand, often followed by rapid relief after resting or sublingual nitroglycerin intake.
② unstable angina pectoris: is characterized in that the chest pain attack has no obvious relation with the increase of myocardial oxygen demand, and compared with stable angina pectoris, the pain generally has longer duration and heavier degree and is not easy to be relieved by nitroglycerin. The pattern is not changed by enzyme, and the electrocardiogram usually has temporary S-T section depression change.
Diagnosis standard of hypertension: in the case of no antihypertensive drug, the systolic pressure is not less than 140mmHg and/or diastolic pressure is not less than 90mmHg, which are measured 3 times on different days, and hypertension can be diagnosed.
1.2.3 grading Standard of chest pain severity
The method is mild: typical angina pectoris attacks, each lasting minutes, pain attacks at least 2-3 times per week or 1-3 times per day, but the pain is not severe and sometimes nitroglycerin is needed;
moderate degree: typical angina pectoris attacks are carried out for several times every day, the pain lasts for several minutes to about 10min each time, and nitroglycerin is generally needed to be taken;
③ the degree of gravity: the typical angina pectoris attacks many times every day, so that daily life (such as defecation and dressing) is influenced, the duration of each attack is long, and the nitroglycerin needs to be sucked many times.
1.2.4 dizziness grading standard
The method is mild: dizziness, which is stopped when the patient feels dizzy;
moderate degree: the visual object rotates and can not walk;
③ the degree of gravity: vertigo, fainting and incapability of standing.
1.2.5 case inclusion criteria
Has main symptoms of thoracic obstruction and vertigo, is definitely diagnosed, and accords with the western medicine diagnosis standard and the traditional Chinese medicine syndrome of angina pectoris complicated with hypertension with phlegm stagnation and obstruction as well as liver depression and dampness obstruction.
1.2.6 exclusion criteria
The first one is proved by various examinations to be patients with myocardial infarction or other heart diseases, intractable hypertension, severe neurosis, and vertigo caused by brain and neck diseases.
② patients with hypertension of more than moderate degree, severe heart and lung insufficiency, serious primary diseases of liver, kidney and hemopoietic system and psychonoses.
③ those under 18 years old or pregnant women who are allergic to the medicine.
Fourthly, the medicine does not meet the inclusion standard, the curative effect cannot be judged if the medicine is not taken according to the regulation, or the data is not complete, and the curative effect or the safety judgment is influenced.
Exclude other heart diseases complicated with hypertension.
2. Patient grouping and treatment method
Dividing the patients into a treatment group and a control group; all anti-angina drugs are not taken in two groups of patients 2 weeks before treatment, and nitroglycerin tablets can be taken when angina attacks.
Treatment groups: after 2 weeks, the capsules provided in example 3 of the present invention were taken 2-3 capsules/time, 1-3 times/day.
Control group: orally administering DIOXINXUEKANG soft capsule (Chengdu DIOXIKANG group, Inc.) 2 granules/time (3 times/day) after 2 weeks; tablet for refreshing brain and lowering blood pressure (sunflower pharmaceutical group, Bio-pharmaceuticals, Ltd.) is administered at a dose of 5 pills/time, 3 times/day.
In the two treatment periods, the nitroglycerin tablets are temporarily taken when angina pectoris attacks, nifedipine tablets are temporarily taken by patients with blood pressure aggravation, other anti-angina and antihypertensive medicines are forbidden, one treatment course is 6 days, the two groups are treated for 7 treatment courses, and low-salt low-fat light diet is given at the same time.
3. Observation of therapeutic effects
3.1 therapeutic criteria for symptoms
The medicine is mild and has obvious effect: the symptoms disappear or substantially disappear. The method has the following advantages: the attack frequency, degree and duration of chest pain, dizziness and headache are obviously reduced. And (4) invalidation: the symptoms were essentially the same as before treatment.
Moderate degree, obvious effect: the symptoms disappear or substantially disappear. The method has the following advantages: the symptoms were reduced to the "mild" standard. And (4) invalidation: the symptoms were essentially the same as before treatment.
③ more severe, effect is shown: symptoms substantially disappear or are reduced to the "mild" standard. The method has the following advantages: the symptoms were reduced to the "moderate" standard. And (4) invalidation: the symptoms were essentially the same as before treatment.
Fourthly, the medicine is severe and has obvious effect: the symptoms have substantially disappeared or alleviated to the "moderate" criteria. The method has the following advantages: the symptoms were alleviated to below the "more severe" criteria. And (4) invalidation: the symptoms were essentially the same as before treatment.
3.2 electrocardiogram curative effect standard:
the method has the following advantages: the electrocardiogram is restored to "approximately normal" or reaches a "normal electrocardiogram".
Secondly, the method is effective: the S-T segment is lowered to raise the T wave back to over 0.05mv after treatment, but not to reach the normal level, the T wave becomes shallow (over 25 percent) when the main lead is inverted, or the T wave changes from flat to upright, and the atrioventricular or indoor conduction block is improved.
③ invalid: the electrocardiogram was substantially the same as before treatment.
3.3 blood pressure curative effect standard:
the method has the following advantages: the diastolic pressure is reduced by more than 10mmHg and reaches the normal range; or the diastolic blood pressure has not decreased to normal but has decreased by 20mmHg or more.
Secondly, the method is effective: the diastolic blood pressure is reduced by less than 10mmHg, but reaches the normal range; or the diastolic pressure is reduced by 10-19 mmHg compared with the diastolic pressure before treatment, but the diastolic pressure is not within the normal range; or the systolic blood pressure is reduced by more than 30mmHg compared with the former systolic blood pressure. One of them is required.
③ invalid: those which do not meet the above criteria.
4. Results of clinical trials
TABLE 2 statistics of clinical trial results
| Group of | Number of examples | Show effect | Is effective | Invalidation | Clinical efficacy (%) | Total effective rate (%) |
| Treatment group | 100 | 82 | 16 | 2 | 82 | 98* |
| Control group | 100 | 67 | 17 | 16 | 67 | 84 |
Note: p <0.05 compared to control.
Table 2 shows that the total effective rates of the two groups are compared and have obvious statistical difference (P <0.05) as shown in table 2, which indicates that the curative effect of the oral Chinese medicinal composition for treating angina pectoris complicated with hypertension is better than that of the conventional Chinese patent medicine.
5. Safety feature
The results of analysis and clinical observation show that after 100 patients in a treatment group take the traditional Chinese medicine composition, the blood routine, the urine routine and the feces routine have no abnormal change, the blood sugar has no abnormal change, the blood fat of the patients accompanied with the blood fat increase is reduced, no obvious toxic or side effect is caused to the renal function, and the traditional Chinese medicine composition is safe and reliable to take. In conclusion, the traditional Chinese medicine composition has the advantages of obvious curative effect on patients with angina and hypertension and small toxic and side effect, and the preparation process is stable and simple. The invention further shows that the traditional Chinese medicine composition has better market application prospect.
Three, typical cases
1. Qin, male, age 35, official. The doctor visits 2 months and 1 day in 2010. The patients suffered from angina pectoris for 2 years and hypertension for 3 years. The patient intermittently attacks the precordial distress and pain, can radiate to the left shoulder when the working pressure is aggravated, has symptoms of dizziness, heavy body and yellow phlegm vomiting after the morning, can be relieved after the patient has a rest, and can be relieved after long-time oral nitroglycerin taking. In the last two months, the symptoms are aggravated due to heavy traffic, and the attack is frequent to see a doctor all the time. And (3) electrocardiogram report: the anterior V4 lead ST segment is shifted horizontally down by about 1.6mv, with the T wave inverted. Blood pressure 154/90 mmHg. Poor sleep at night, small stool, sticky stool, pale and dark red tongue with greasy coating, and slippery pulse. And (3) Western diagnosis: angina pectoris with hypertension. Traditional Chinese medicine diagnosis: thoracic obstruction and vertigo. Syndrome differentiation: phlegm and blood stasis are combined together, and dampness and turbidity are endogenous. Therapeutic method: promoting blood circulation, relieving pain, eliminating phlegm, and eliminating dampness. The oral administration of the oral pharmaceutical composition for treating angina pectoris complicated with hypertension of the embodiment 1 of the present invention is 3 times a day, 2 granules each time, and the chest distress is relieved, the attack frequency is reduced, and the dizziness is obviously relieved after one week of administration. The patient hopes to continue taking the medicine, the original prescription is added or subtracted for two months, the symptoms are completely relieved, the electrocardiogram is rechecked for many times, the ST segment is recovered to be normal, the blood pressure is reduced to 130-140/85-90 mmHg, and the daily activities are not limited. The patient was ordered a low salt, low fat diet and was properly active at ordinary times.
2. Zheng, male, 38 years old, retired pilot. Visit 2/7/2012. The patient is healthy at ordinary times, the ST segment of the electrocardiogram is found to be depressed when the army is physically examined three years ago, the heart rate is 92 times/minute, and the patient is diagnosed as myocardial ischemia. During the work, the patient has some problems, such as transient angina pectoris, headache, dizziness, bitter taste and sticky mouth in the morning and palpitation. Blood pressure: 146/89 mmHg. Emotional anxiety, poor sleep, yellow urine, and unclean stool, which is always convenient. Dark red tongue with greasy coating. The pulse is slippery and astringent. And (3) Western diagnosis: angina pectoris with hypertension. Traditional Chinese medicine diagnosis: thoracic obstruction and vertigo. Syndrome differentiation: phlegm-stasis obstructing the liver-qi. Therapeutic method: disperse blood stasis, alleviate pain, dispel phlegm, soothe the liver, promote qi circulation and remove dampness. The oral administration of the oral pharmaceutical composition for treating angina pectoris complicated with hypertension of embodiment 3 of the present invention is 3 times a day, 2 granules each time, the number of angina pectoris times after 1 month of administration is obviously reduced compared with before, chest distress is relieved, and dizziness is obviously relieved. After the original prescription is added and reduced for treatment for 4 weeks, the symptoms of the patient are completely relieved, the ST segment of the electrocardiogram is rechecked to restore to normal, the blood pressure is reduced to 125-140/80-90 mmHg, and the daily activities are basically not limited. After one year follow-up, the patient complains of vertigo/chest distress and pain without relapse.
3. Qi in the morning, woman, age 52, left retired. The doctor visits 3, 7 days in 2013. Angina pectoris 5 years, hypertension 6 years, and hyperlipidemia 2 years. Patients complain of difficult vertigo, vomiting phlegm and saliva, no food intake, mental anxiety and difficulty in falling asleep before three days, and feel stuffy in chest and have chest pain for several times during 2-3 am, and the patients can be diagnosed today. Electrocardiogram: sinus rhythm, T wave changes. Blood pressure: 150/93 mmHg. Dizziness, chest distress and chest pain, vomiting phlegm and saliva, poor appetite, aggravation after fatigue, palpitation and hypodynamia, poor sleep, loose stool and small stool. The tongue is red and the coating is thick and greasy. The pulse is smooth and rapid. Deny the history of drug and food allergies. And (3) Western diagnosis: angina pectoris with hypertension. Traditional Chinese medicine diagnosis: thoracic obstruction and vertigo. Syndrome differentiation: phlegm-stasis obstructing the stomach. Therapeutic method: dispel phlegm, relieve dizziness, invigorate spleen and resolve dampness. The oral medicine composition for treating angina pectoris complicated with hypertension is orally taken 2 times a day, 6 granules are taken each time, and the medicine composition is continuously taken for 3 weeks, so that after patients complain of the medicine, chest distress, dizziness and pain are obviously relieved earlier, the body is vigorous earlier, sleep can be taken, and defecating and urination can be performed. After taking for 3 months, the electrocardiogram shows that the ST segment is recovered to be normal, and the blood pressure is: 130-140/70-90 mmHg. Half a year of follow-up, the patient did not complain of discomfort.
4. Tan someone, women, 68 years old, farmers. The doctor will see 3 months and 12 days in 2014. The patient has sudden chest pain caused by house work noise 4 hours ago, each time lasts for about 2 minutes, and the patient can be diagnosed with dizziness, vomiting phlegm and saliva when doing so. The symptoms are as follows: chest pain, chest distress, heavy precordial region, dizziness with intermittent headache, vomiting phlegm and saliva, and no pain in chest. Clear mind, fat body, mental anxiety, sticky and greasy mouth, poor sleep, sticky stool and small stool. The tongue is red and dark, and the coating is thick and greasy. And (3) electrocardiogram prompting: ST segment moves down, and T wave is inverted. Blood pressure: 142/101mmHg deny the history of drug and food allergies. And (3) Western diagnosis: angina pectoris with hypertension. Traditional Chinese medicine diagnosis: thoracic obstruction and vertigo. Syndrome differentiation: liver qi stagnation with phlegm-dampness and blood stasis obstructing the heart vessels. Therapeutic method: soothing liver, eliminating phlegm, eliminating dampness, promoting blood circulation, removing blood stasis and relieving pain. The oral administration of the pharmaceutical composition for treating angina pectoris complicated with hypertension of the present invention is 2 times a day, 5 granules each time; after patients complain about the medicine application for three weeks, the subjective symptoms are better than before, the symptoms of the patients are obviously improved after the patients take the medicine continuously for five months, and the medicine application is continued to consolidate the curative effect. Reviewing the electrocardiogram representation: the ST segment and the T wave are recovered to be normal, and the blood pressure is as follows: 133-140/70-85 mmHg, half a year of follow-up, good condition and no recurrence.
It should be noted that when the following claims refer to numerical ranges, it should be understood that both ends of each numerical range and any value between the two ends can be selected, and since the steps and methods used are the same as those of the embodiments, the preferred embodiments of the present invention have been described for the sake of avoiding redundancy, and although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to the embodiments once they learn the basic inventive concept. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be construed as the protection scope of the present invention.
Claims (6)
1. The traditional Chinese medicine composition for treating angina pectoris complicated with hypertension is characterized by being prepared from the following raw material medicines in parts by weight:
10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of loranthus parasiticus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae;
the preparation process of the traditional Chinese medicine composition comprises the following steps:
s1: weighing 10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of parasitic loranthus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae according to parts by weight for later use;
s2: mixing the raw materials weighed by S1, adding ethanol 4-8 times of the total weight of the raw materials, soaking for 1-1.5 h, extracting at 30-35 deg.C for 1-1.5 h for 2-4 times, filtering to obtain residue, and mixing extractive solutions; filtering the extracting solution by using a 100-150-mesh filter screen, then carrying out ultrafiltration by using an ultrafiltration column with the cut-off molecular weight of 5000-12000, carrying out reduced pressure concentration on the ultrafiltrate to obtain an extract with the relative density of 1.2-1.25 at 65-75 ℃, and standing to obtain a component alpha;
s3: adding 8-12 times of distilled water into the residue extracted by the ethanol of S2, heating and refluxing for extraction for 2-4 times, each time for 1.0-2.5 h, mixing the extractive solutions, and standing to obtain a component beta;
s4: mixing alpha and beta, filtering, concentrating under reduced pressure to obtain medicinal liquid with concentration of 1.0-1.2 g/mL, refining and purifying to obtain Chinese medicinal extract, and making the extract into pharmaceutically acceptable medicinal preparation by conventional method of Chinese patent medicine.
2. The traditional Chinese medicine composition for treating angina pectoris complicated with hypertension according to claim 1 is characterized by being prepared from the following raw material medicines in parts by weight:
10-25 parts of pseudo-ginseng, 6-25 parts of salvia miltiorrhiza, 5-20 parts of earthworm, 6-30 parts of ligusticum wallichii, 8-30 parts of corydalis tuber, 12-30 parts of gastrodia elata, 8-30 parts of uncaria, 6-15 parts of antelope horn, 10-20 parts of loranthus parasiticus, 5-15 parts of chrysanthemum, 5-20 parts of rhizoma alismatis, 8-35 parts of medicinal cyathula root, 6-30 parts of trichosanthes kirilowii maxim and 6-15 parts of pericarpium citri reticulatae.
3. The preparation method of the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension according to claim 1, characterized by comprising the following steps:
s1: weighing 10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of parasitic loranthus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae according to parts by weight for later use;
s2: mixing the raw materials weighed by S1, adding ethanol 4-8 times of the total weight of the raw materials, soaking for 1-1.5 h, extracting at 30-35 deg.C for 1-1.5 h for 2-4 times, filtering to obtain residue, and mixing extractive solutions; filtering the extracting solution by using a 100-150-mesh filter screen, then carrying out ultrafiltration by using an ultrafiltration column with the cut-off molecular weight of 5000-12000, carrying out reduced pressure concentration on the ultrafiltrate to obtain an extract with the relative density of 1.2-1.25 at 65-75 ℃, and standing to obtain a component alpha;
s3: adding 8-12 times of distilled water into the residue extracted by the ethanol of S2, heating and refluxing for extraction for 2-4 times, each time for 1.0-2.5 h, mixing the extractive solutions, and standing to obtain a component beta;
s4: mixing alpha and beta, filtering, concentrating under reduced pressure to obtain medicinal liquid with concentration of 1.0-1.2 g/mL, refining and purifying to obtain Chinese medicinal extract, and making the extract into pharmaceutically acceptable medicinal preparation by conventional method of Chinese patent medicine.
4. The method for preparing a Chinese medicinal composition for treating angina pectoris complicated with hypertension according to claim 3, wherein in S4, the specific process of refining and purifying is as follows:
adsorbing the concentrated medicinal liquid with macroporous adsorbent resin column, eluting with 10-12 times of distilled water, eluting with 4-6 times of ethanol, collecting ethanol eluate, and removing solvent to obtain Chinese medicinal extract.
5. The preparation method of the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension according to claim 1, characterized by comprising the following steps:
step 1: weighing 10-30 parts of pseudo-ginseng, 6-30 parts of salvia miltiorrhiza, 5-25 parts of earthworm, 6-36 parts of ligusticum wallichii, 8-32 parts of corydalis tuber, 12-36 parts of gastrodia elata, 8-36 parts of uncaria, 6-18 parts of antelope horn, 10-24 parts of parasitic loranthus, 5-20 parts of chrysanthemum, 5-25 parts of rhizoma alismatis, 8-36 parts of medicinal cyathula root, 6-32 parts of trichosanthes kirilowii maxim and 6-18 parts of pericarpium citri reticulatae according to parts by weight for later use;
step 2: crushing the raw materials weighed in the step 1 into particles, soaking the particles in water for 1-2 hours to enable the medicines to be thoroughly wetted, then adding water with the weight being 8-12 times that of the raw materials into the raw materials for decocting, boiling the raw materials with strong fire, changing the raw materials into slow fire after the water is boiled, decocting for 1.5-2 hours, filtering to obtain liquid medicine, and separating medicine residues;
adding water with the amount of 3-6 times of the medicinal materials into the residue, decocting for 1-2 hr, filtering to obtain medicinal liquid, separating out residue, and repeatedly extracting the residue for 2-3 times;
filtering the decoctions, and mixing to obtain filtrate;
and step 3: concentrating the filtrate obtained in step 2 under reduced pressure to obtain concentrated solution with relative density of 1.1-1.2 at 70-80 deg.C, and standing at 0-5 deg.C for 18-24 hr to obtain refrigerated solution;
and 4, step 4: mixing the refrigerating fluid obtained in the step 3 with diatomite according to the weight ratio of 1:2, filtering, concentrating the filtrate under reduced pressure, drying into powder, and preparing the powder into a pharmaceutically acceptable medicinal preparation according to a conventional method.
6. The preparation method of the traditional Chinese medicine composition for treating angina pectoris complicated with hypertension according to claim 3 or 5, wherein the pharmaceutical dosage form of the pharmaceutical preparation is tablet, capsule, granule or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910577444.4A CN110151922B (en) | 2019-06-28 | 2019-06-28 | Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910577444.4A CN110151922B (en) | 2019-06-28 | 2019-06-28 | Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110151922A CN110151922A (en) | 2019-08-23 |
| CN110151922B true CN110151922B (en) | 2021-08-17 |
Family
ID=67637447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910577444.4A Active CN110151922B (en) | 2019-06-28 | 2019-06-28 | Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110151922B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788749A (en) * | 2005-10-20 | 2006-06-21 | 北京汉典中西药研究开发中心 | Preparation method of capsule containing red sage root and notoginseng |
| CN104189113A (en) * | 2014-09-02 | 2014-12-10 | 烟台恒迪克能源科技有限公司 | Salvia miltiorrhiza compound hypotensive capsule and preparation method thereof |
| CN108295177A (en) * | 2018-03-27 | 2018-07-20 | 南阳理工学院 | It is a kind of to be used to treat Chinese medicine composition of coronary disease and angina pectoris and preparation method thereof |
-
2019
- 2019-06-28 CN CN201910577444.4A patent/CN110151922B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788749A (en) * | 2005-10-20 | 2006-06-21 | 北京汉典中西药研究开发中心 | Preparation method of capsule containing red sage root and notoginseng |
| CN104189113A (en) * | 2014-09-02 | 2014-12-10 | 烟台恒迪克能源科技有限公司 | Salvia miltiorrhiza compound hypotensive capsule and preparation method thereof |
| CN108295177A (en) * | 2018-03-27 | 2018-07-20 | 南阳理工学院 | It is a kind of to be used to treat Chinese medicine composition of coronary disease and angina pectoris and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 功补兼施法治疗冠心病心绞痛50例临床体会;张成元等;《青海医药杂志》;20090120;第39卷(第01期);第67页左栏第4，7段 * |
| 川芎钩藤方配合尼群地平治疗高血压病30例临床观察;唐平等;《四川医学》;20090315;第30卷(第03期);第398页左栏第1，5段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110151922A (en) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN108524673A (en) | A kind of Chinese medicine composition and its application | |
| CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
| CN108403882B (en) | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof | |
| CN111135235A (en) | A composition for preventing and relieving acute alcoholism or alcoholic intoxication | |
| CN110151922B (en) | Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof | |
| CN111558019B (en) | Traditional Chinese medicine composition with effects of benefiting qi, nourishing blood, regulating menstruation and relieving pain and preparation method and application thereof | |
| CN111529659A (en) | Traditional Chinese medicine composition for treating bradyarrhythmia and preparation method and application thereof | |
| CN104547494A (en) | Traditional Chinese medicine composition medicinal liquor for treating hyperthyroidism and preparation process | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN108743757A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating insomnia | |
| CN104857121A (en) | Drug combination for curing hyperlipidemia and application thereof | |
| CN103961578A (en) | Traditional Chinese medicine medicinal liquor for treating neurasthenia | |
| CN114848724B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN112206279B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and preparation method and application thereof | |
| CN115414427B (en) | Traditional Chinese medicine composition for treating chronic skin pruritus and preparation method and application thereof | |
| CN108079113A (en) | A kind of pharmaceutical composition for treating the postpartum deficiency of blood and preparation method thereof | |
| CN114246900B (en) | Traditional Chinese medicine extract for treating hypertension and preparation method and pharmaceutical application thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN110464774B (en) | Compound propranolol hydrochloride oral liquid for treating infantile hemangioma | |
| CN101607007B (en) | Traditional Chinese medicine preparation for treating cerebral circulation insufficiency | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN104706942A (en) | Medicine composition for treating cerebrocardiac syndrome and preparation method of medicine composition | |
| CN103356984B (en) | Traditional Chinese medicine composition for preventing and treating female iron deficiency anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |